Similar articles

• Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study.

  Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, Wiedemann P, Simader C, Gekkieva M, Weichselberger A; EXCITE Study Group. Schmidt-Erfurth U, et al. Ophthalmology. 2011 May;118(5):831-9. doi: 10.1016/j.ophtha.2010.09.004. Epub 2010 Dec 13. Ophthalmology. 2011. PMID: 21146229 Clinical Trial.
• Systemic safety of bilateral intravitreal anti-vascular endothelial growth factor injections.

  Freund KB, Vance SK. Freund KB, et al. Retina. 2011 Jan;31(1):1-3. doi: 10.1097/IAE.0b013e318203c0ef. Retina. 2011. PMID: 21187729 No abstract available.
• Treatment of macular degeneration--controversy and hope.

  McGimpsey SJ, Gillies MC. McGimpsey SJ, et al. Br J Ophthalmol. 2008 Mar;92(3):436-7. doi: 10.1136/bjo.2007.125070. Br J Ophthalmol. 2008. PMID: 18314407 No abstract available.
• Ocular microparticle formulations for 6-month delivery of anti-VEGF.

  Park K. Park K. J Control Release. 2016 Dec 28;244(Pt A):136. doi: 10.1016/j.jconrel.2016.12.001. J Control Release. 2016. PMID: 27964806 Review. No abstract available.
• Aflibercept (eylea) for age-related macular degeneration.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2012 Feb 6;54(1383):9-10. Med Lett Drugs Ther. 2012. PMID: 22354219 Review. No abstract available.